30-day average of 18 articles · scale −100 to +100
Across 18 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Bristol-Myers Squibb Company news is Somewhat Bullish (+40)
on a scale from −100 to +100.
That is up 10 points from the previous 30 days (+30).
📈 BMY stock returned 40.5% over three years, trading near $62.91.
💰 Company generated $9.3 billion in free cash flow last twelve months.
Slightly Bullish +15
Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% ...
AI-generated analysis
Key insights
📈 BMY stock has returned approximately 40.5% over the past three years, trading near $62.91 per share.
💰 The company generated about $9.3 billion in free cash flow over the last twelve months according to the analysis.
🔬 Recent positive data for Camzyos and new approvals for ZENBEXUS are expected to support future drug-driven cash flows.
⚠️ Investors face a projected revenue step-down from Eliquis beginning in 2027 as part of the company's lifecycle management.
💡 A bullish narrative suggests BMY is 21% undervalued if late-stage platforms like CAR-T and ADCs succeed commercially.
📉 A bearish perspective argues the stock is 121% overvalued at current levels, with price being the primary sticking point.
💸 The company has implemented a plan to generate $2 billion in cost savings to offset revenue shifts.
🧠 Simply Wall St analysis indicates the fair value depends on successfully converting late-stage platforms into meaningful products.
📈 Bullish signals
🔬Recent trial results for Camzyos and new product approvals for ZENBEXUS are expected to support expectations for future drug-driven cash flows.
💡The company has a solid pipeline story with late-stage platforms in areas like CELMoDs, CAR-T, ADCs, Factor XI inhibition, and neuroscience that could convert into commercially meaningful products.
💡A bullish analyst narrative suggests the stock is 21% undervalued if the company successfully manages revenue transitions from legacy assets like Eliquis.
📉 Risk factors
💰The DCF model assumes a gently declining free cash flow pattern over the next decade as major products mature and new launches fill gaps only gradually.
📉A bearish investor narrative argues the stock is 121% overvalued at current levels, stating that the entry price exceeds fair value filters despite the company's quality.
⚠️The analysis projects a step-down in revenue from Eliquis starting in 2027, which constrains growth assumptions in the valuation model.
Article
Bristol-Myers Squibb (BMY) shares have appreciated approximately 40.5% over the past three years, trading around $62.91 per share. The article analyzes whether this valuation is justified by the company's long-term cash flow generation capabilities, utilizing a Discounted Cash Flow (DCF) model that projects free cash flow of roughly $9.3 billion over the last twelve months.
The analysis suggests BMY may be undervalued based on intrinsic value calculations derived from its cash flow profile. Key drivers supporting this view include recent positive trial results for Camzyos and new product approvals for ZENBEXUS, which are expected to bolster future drug-driven cash flows despite anticipated revenue declines from the legacy asset Eliquis starting in 2027.
Simply Wall St presents a split narrative regarding BMY's fair value. A bullish perspective argues the stock is 21% undervalued if the company successfully commercializes its late-stage platforms in areas like CAR-T and ADCs while managing revenue transitions. Conversely, a bearish view contends the stock is 121% overvalued at current levels, citing that the entry price exceeds fair value filters despite the underlying quality of the business.
The article concludes by emphasizing the importance of leadership strategy in shaping BMY's future trajectory. It notes that while the company has a solid pipeline and cost-saving plans totaling $2 billion, investors must weigh these factors against the specific assumptions regarding growth margins and earnings required to justify the current market price.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Company updateDividendEarnings reportAI-generated analysis
Bristol-Myers Squibb (NYSE:BMY) is navigating a critical transition period where its investment story is shifting from reliance on older blockbuster drugs facing patent expiration to newer medicines driving growth. The company's latest financial results indicate progress in this strategic pivot, with its Growth Portfolio generating $7.6 billion in revenue during the second quarter of 2026, representing a 15% year-over-year increase and now accounting for nearly 60% of total revenue.
The company reported total revenue of $12.97 billion for the quarter, up 6% year over year, while Non-GAAP EPS climbed 40% to $2.04. Consequently, Bristol Myers raised its full-year 2026 outlook, projecting revenue between $49 billion and $50 billion and Non-GAAP EPS between $6.75 and $7.00. Key growth drivers include Reblozyl, Camzyos, Breyanzi, Opdualag, and Eliquis, with Eliquis revenue increasing 22% in the quarter.
Despite the positive momentum from newer drugs, legacy revenue declined 4% due to generic competition, highlighting the necessity of the portfolio shift. The stock trades at approximately 9.4 times forward earnings and offers a dividend yield of roughly 4.1%, positioning it as an attractive high-yield pharmaceutical investment with a solid moat built on intellectual property and scale, though investors must monitor if new drug growth can fully offset future patent losses.
📈 Q2 2026 revenue hit $12.97B, up 6% year-over-year.
💰 Non-GAAP EPS surged 40% to $2.04 in the quarter.
🚀 Raised 2026 guidance to $49-$50B revenue and $6.75-$7.00 EPS.
⚠️ Legacy drug revenue declined 4% due to generic competition.
📉 Stock trades at 9.4x forward earnings, below 10x valuation.
📈 Bristol Myers' Growth Portfolio generated $7.6 billion in Q2 2026 revenue, a 15% increase year-over-year, now comprising nearly 60% of total revenue.
💰 Total company revenue reached $12.97 billion in the quarter, up 6%, while Non-GAAP EPS surged 40% to $2.04.
🚀 The company raised its 2026 full-year guidance to expect $49-$50 billion in revenue and $6.75-$7.00 in Non-GAAP EPS.
💊 Key growth drivers Reblozyl, Camzyos, Breyanzi, Opdualag, and Eliquis all posted revenue increases, with Eliquis up 22%.
⚠️ Legacy drug revenue declined 4% due to generic competition, underscoring the critical need for newer portfolio growth.
📉 The stock trades at 9.4 times forward earnings, reflecting a valuation that has recovered from earlier patent-cliff concerns but remains below 10x.
💵 Bristol Myers offers an annualized dividend of $2.52 per share, yielding approximately 4.1% with a payout ratio around 55%.
🛡️ The company maintains a strong moat through intellectual property, drug development capabilities, and global sales infrastructure.
📅 Morningstar forecasts 2028 as a significant patent-loss year, requiring new launches to offset revenue from expiring older medicines.
Bullish Signals
Growth Portfolio grew 15% YoY to $7.6B in Q2 2026.
Risk Factors
Legacy drug revenue declined 4% due to generic competition.
Eliquis and Opdivo face patent expiration concerns impacting future revenue.
Morningstar expects 2028 major patent-loss year pressuring new launches.
Bullish Signals
Bristol Myers' Growth Portfolio grew 15% year-over-year to $7.6 billion in Q2 2026, now representing nearly 60% of total revenue.
Non-GAAP EPS increased 40% to $2.04 in the quarter, demonstrating strong profitability from newer medicines.
The company raised its 2026 full-year guidance, projecting revenue between $49 billion and $50 billion.
Eliquis revenue increased 22% during the quarter, continuing to serve as a major contributor to top-line growth.
Opdivo Qvantig revenue jumped more than 200%, indicating strong uptake in this newer oncology product.
The stock trades at 9.4 times forward earnings, suggesting the market has adjusted its valuation away from severe patent-cliff fears.
Bristol Myers offers an attractive dividend yield of roughly 4.1% with a sustainable payout ratio of around 55%.
Risk Factors
Legacy drug revenue declined 4% in the quarter as generic competition intensified for several established products.
Eliquis and Opdivo face longer-term patent expiration concerns that could impact future revenue streams.
Morningstar expects 2028 to be a major patent-loss year, creating pressure on the company to offset declines with new launches.
Bristol Myers Squibb shares traded at EUR 54.56 in pre-market trading on October 5, 2026, representing a modest gain of 0.26 percent against the previous close of EUR 54.42 recorded on October 2. The stock displayed a bid-ask spread ranging from EUR 54.34 to EUR 54.77 at the time of the report, indicating standard liquidity conditions ahead of the market open.
The company's board officially declared a quarterly dividend of USD 0.63 per share in a press release dated September 16, 2026. This dividend is scheduled to be payable on November 2, 2026, to shareholders who are recorded as owners at the close of business on October 2, 2026.
Looking ahead, Bristol Myers Squibb confirmed that it will release its third-quarter 2026 financial results on October 29, 2026. The company plans to host a conference call beginning at 8:00 a.m. Eastern Time to discuss the earnings, with related materials available on its investor relations website prior to the event.
📈 BMY stock traded up 0.26% to EUR 54.56 in pre-market trading.
💰 Quarterly dividend of USD 0.63 per share declared for record Oct 2.
📅 Third-quarter 2026 financial results and conference call scheduled for Oct 29.
📈 Bristol Myers Squibb stock traded at EUR 54.56 in pre-market trading on October 5, 2026, up 0.26 percent from the prior close.
💰 The company declared a quarterly dividend of USD 0.63 per share payable to shareholders of record on October 2, 2026.
📅 Bristol Myers Squibb will announce its third-quarter 2026 financial results on October 29, 2026, followed by an earnings conference call.
🏢 The stock was listed with a bid of EUR 54.34 and an ask of EUR 54.77 at 7:51 a.m. CEST on the reporting date.
Bullish Signals
Shares gained 0.26% in pre-market trading.
Declared quarterly dividend of USD 0.63 per share.
Bullish Signals
Bristol Myers Squibb shares gained 0.26 percent in pre-market trading, closing higher than the previous session's price.
The company declared a quarterly dividend of USD 0.63 per share, providing income to shareholders of record on October 2, 2026.
Bristol Myers Squibb (NYSE: BMY) is currently trading at approximately 9.4x forward earnings, significantly below the 18.5x average for healthcare stocks, presenting a potential value opportunity despite recent patent cliffs affecting its top-selling drugs like Revlimid.
The company's financial performance in the second quarter showed resilience with revenue increasing 6% year-over-year to $13 billion and non-GAAP earnings per share jumping 40% to $2.04, driven largely by Eliquis and Opdivo which together accounted for over half of total revenue.
To mitigate future risks from patent expirations on Eliquis and Opdivo, Bristol Myers is leveraging new formulations like the subcutaneous Opdivo Qvantig and growing its pipeline with candidates such as pumitamig and milvexian to replace declining sales.
Beyond product innovation, the stock offers an attractive 4% forward dividend yield compared to the S&P 500 average of 1.1%, supported by a decade-long payout increase of 65.8%, making it a candidate for long-term income-focused investors.
📉 BMY trades at 9.4x forward earnings vs 18.5x sector average, signaling undervaluation.
💰 Q2 revenue rose 6% to $13B with non-GAAP EPS up 40% to $2.04.
🧬 Eliquis and Opdivo drive over half revenue but face decade-end patent losses.
💉 Opdivo Qvantig launch aims to retain patients as original formulation loses exclusivity.
💵 BMY offers 4% dividend yield, up 65.8% over the last decade.
📉 Bristol Myers Squibb trades at just 9.4x forward earnings versus an 18.5x sector average, signaling potential undervaluation.
💰 The company reported a 6% year-over-year revenue increase to $13 billion in the second quarter with non-GAAP EPS rising 40% to $2.04.
🧬 Key assets Eliquis and Opdivo contributed over half of total revenue, though both face patent exclusivity losses by the end of the decade.
💉 The launch of Opdivo Qvantig aims to retain patients from the original formulation as it loses patent protection through easier administration.
🔬 Bristol Myers is developing pumitamig in partnership with BioNTech and milvexian as potential successors to its expiring blockbuster drugs.
💵 The stock offers a 4% forward dividend yield, significantly higher than the S&P 500 average of 1.1%, with payouts increased by 65.8% over the last decade.
Bullish Signals
Trades at 9.4x forward earnings vs 18.5x peers.
Q2 revenue up 6% to $13B; EPS +40%.
Launched Opdivo Qvantig to retain patients post-patent.
Pipeline replaces revenue from Eliquis and Opdivo cliffs.
Offers 4% yield, triple S&P 500 average.
Risk Factors
Generic/biosimilar competition may slow/reverse Eliquis/Opdivo growth.
Bullish Signals
Bristol Myers Squibb is trading at a low valuation of 9.4x forward earnings compared to the 18.5x average for healthcare peers.
Second-quarter revenue grew 6% year-over-year to $13 billion while non-GAAP EPS surged 40% to $2.04.
The company successfully launched Opdivo Qvantig, a subcutaneous version of its cancer drug that may help retain patients as the original formulation loses patent exclusivity.
Bristol Myers has a robust pipeline including pumitamig and milvexian designed to replace revenue lost from upcoming patent cliffs on Eliquis and Opdivo.
The stock provides an attractive 4% forward dividend yield, more than triple the S&P 500 average of 1.1%, with a history of increasing payouts by 65.8% over the past decade.
Risk Factors
The market anticipates that generic and biosimilar competition for Eliquis and Opdivo could cause revenue and earnings growth to slow or reverse in the coming years.
Bristol Myers Squibb (BMY) traded at EUR 54.10 in after-hours trading on October 2, 2026, with a bid of EUR 53.99 and an ask of EUR 54.21 according to Lang & Schwarz.
The company received FDA approval for its drug CAMZYOS for treating symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing at least 30 kilograms. This regulatory milestone was based on data from the Phase 3 SCOUT-HCM trial, which enrolled 44 adolescent patients.
Additionally, Bristol Myers Squibb announced a $1 million grant program for nonprofit organizations supporting medically underserved communities in the United States, with nominations due by November 30, 2026.
📈 BMY stock traded at EUR 54.10 after-hours on October 2, 2026.
💊 FDA approved CAMZYOS for adults and pediatric patients (≥30kg) with obstructive HCM.
👶 Approval relies on Phase 3 SCOUT-HCM trial results from 44 adolescent patients.
🤝 BMY announced a $1 million grant program for nonprofits supporting underserved communities.
📅 Grant nominations are due by November 30, 2026.
📈 BMY stock traded at EUR 54.10 after-hours on October 2, 2026.
💊 FDA approved CAMZYOS for adults and pediatric patients (≥30kg) with symptomatic obstructive hypertrophic cardiomyopathy.
👶 Approval relies on Phase 3 SCOUT-HCM trial results from 44 adolescent patients.
🤝 BMY announced a $1 million grant program for nonprofits supporting medically underserved communities.
📅 Grant nominations are due by November 30, 2026.
Bullish Signals
FDA approved CAMZYOS for adults and pediatric patients ≥30kg.
Phase 3 SCOUT-HCM trial enrolled 44 adolescents for approval.
Bullish Signals
Bristol Myers Squibb secured FDA approval for CAMZYOS in adults and pediatric patients weighing at least 30 kilograms for symptomatic obstructive hypertrophic cardiomyopathy.
The company's Phase 3 SCOUT-HCM trial successfully enrolled 44 adolescent patients to support the regulatory approval of its new drug indication.
Bristol Myers Squibb (BMY) has announced that it will report its third-quarter financial results on October 29, 2026. This scheduled release serves as a key market checkpoint following the company's strong second-quarter performance in 2026, where revenue reached USD 12.97 billion, representing a 6% increase year-over-year.
During the second quarter of 2026, Bristol Myers Squibb reported GAAP diluted earnings per share of USD 1.62 and net earnings attributable to the company of USD 3.32 billion. The company's Growth Portfolio drove significant expansion with quarterly revenue of USD 7.56 billion, up 15%, while the Legacy Portfolio saw a decline of 4% to USD 5.42 billion.
Regarding shareholder returns, Bristol Myers Squibb declared a quarterly dividend of USD 0.63 per share on September 16, 2026, with the payment scheduled for November 2, 2026, for shareholders of record on October 2, 2026. Analyst Piper Sandler recently raised its price target to USD 82.00 and maintained an Overweight rating, citing continued growth in the company's portfolio mix.
As of late September 2026, Bristol Myers Squibb had a market capitalization of USD 127.5 billion and was trading within a 52-week range of USD 42.52 to USD 68.64. The upcoming Q3 report will be closely watched to determine if the momentum from the second quarter can be sustained.
📅 Q3 earnings results scheduled for October 29, 2026.
💰 Quarterly dividend declared at USD 0.63 per share.
📈 Q2 revenue rose 6% to USD 12.97 billion.
💵 Q2 GAAP EPS reached USD 1.62 with net earnings of USD 3.32 billion.
🚀 Growth Portfolio revenue surged 15% to USD 7.56 billion.
📅 Bristol Myers Squibb has set October 29, 2026, as the date for its third-quarter earnings results.
💰 The company declared a quarterly dividend of USD 0.63 per share payable on November 2, 2026.
📈 Second-quarter 2026 revenue reached USD 12.97 billion, marking a 6% increase from the prior-year quarter.
💵 GAAP diluted earnings per share for the second quarter were USD 1.62 with net earnings of USD 3.32 billion.
🚀 The Growth Portfolio generated USD 7.56 billion in quarterly revenue, up 15% year-over-year.
📉 The Legacy Portfolio revenue declined by 4% to USD 5.42 billion during the second quarter.
🏦 Analyst Piper Sandler raised its price target from USD 75.00 to USD 82.00 and kept an Overweight rating.
📊 As of September 30, 2026, the stock had a market capitalization of USD 127.5 billion.
📉 The stock traded within a 52-week range of USD 42.52 to USD 68.64 as of late September.
The article compares Bristol Myers Squibb (BMY) and Eli Lilly (LLY), positioning BMY as a deep-value dividend payer with a maturing portfolio focused on oncology and hematology blockbusters like Eliquis and Opdivo. In contrast, LLY is characterized as a high-growth juggernaut driven by its dominant position in metabolic treatments for weight loss and diabetes.
Bristol Myers Squibb reported FY 2025 revenue of approximately $48.2 billion, a slight decline of 0.2%, but achieved a net income of roughly $7.1 billion, marking a return to profitability after a prior year's loss with a net margin near 15%. The company maintains a debt-to-equity ratio of nearly 2.6x and generated free cash flow of around $12.8 billion.
Looking forward, analysts project BMY revenue to edge up 3% to roughly $49.8 billion in the current fiscal year, with net income expected to rise more than 40% to $11.2 billion. However, the article notes that while the stock appears cheap due to lower valuation multiples, investors have priced in significant difficulties ahead, making it a less obvious buy compared to LLY's explosive growth trajectory.
The text highlights specific risks for BMY, including pressure from the U.S. Inflation Reduction Act regarding price negotiations and the constant threat of patent expirations leading to rapid revenue declines. Additionally, the company recently ended a manufacturing partnership for its Breyanzi platform, signaling challenges in scaling complex cell therapies and a strategic shift toward internal capabilities.
📉 FY 2025 revenue declined slightly to $48.2 billion.
💰 Net income reached $7.1 billion with a 15% margin.
🏦 Debt-to-equity stands at 2.6x with $12.8B free cash flow.
📈 Analysts forecast FY revenue growth of 3% to $49.8B.
⚠️ IRA price negotiations and patent expirations pose risks.
📉 Bristol Myers Squibb reported FY 2025 revenue of $48.2 billion, representing a slight decline of roughly 0.2% compared to the prior year.
💰 The company returned to profitability in FY 2025 with net income of approximately $7.1 billion and a net margin of roughly 15%.
🏦 As of December 2025, BMY maintained a debt-to-equity ratio of nearly 2.6x and generated free cash flow of around $12.8 billion.
📈 Analysts forecast revenue growth of 3% to approximately $49.8 billion for the current fiscal year with net income rising over 40% to $11.2 billion.
⚠️ BMY faces significant pressure from the U.S. Inflation Reduction Act, which allows government price negotiations on top-selling drugs.
📉 The company is exposed to patent expirations that lead to rapid revenue declines as generic competitors enter the market.
🔬 Bristol Myers Squibb recently ended a manufacturing partnership for its Breyanzi platform due to difficulties in scaling complex cell therapies.
💸 Valuation metrics indicate BMY has lower Forward P/E and P/S ratios compared to Eli Lilly, reflecting a cheaper stock price.
📉 The article concludes that despite low ratios, the stock is not an obvious buy right now due to a hard-to-predict recovery timeline.
Bullish Signals
Net income reached $7.1B in FY 2025 after prior loss.
Free cash flow hit $12.8B, supporting dividends and flexibility.
Revenue projected to rise 3% to $49.8B with income up 40%.
Risk Factors
IRA allows price negotiation on top-selling drugs.
Patent expirations cause rapid revenue declines from generics.
Bristol Myers Squibb returned to profitability in FY 2025 with net income of approximately $7.1 billion after a significant loss in the previous fiscal year.
The company generated strong free cash flow of around $12.8 billion, providing ample room for dividends and financial flexibility.
Analysts project revenue to edge up 3% to roughly $49.8 billion in the current fiscal year with net income rising more than 40% to $11.2 billion.
Risk Factors
Bristol Myers Squibb faces significant pressure from the U.S. Inflation Reduction Act, which allows the government to negotiate prices for its top-selling drugs.
The company deals with the constant threat of patent expirations, where losing exclusivity leads to rapid revenue declines as generic competitors enter the market.
Clinical trial failures or safety warnings on advanced therapies pose risks to BMY's long-term growth pipeline and ability to replace aging brands.
The company recently ended a manufacturing partnership for its Breyanzi platform, highlighting the difficulty of scaling complex cell therapies in a competitive market.
Bristol-Myers Squibb (BMY) shares recently closed at US$63.88, trading below a Discounted Cash Flow (DCF) model's estimated intrinsic value. The company generated approximately $11.5 billion in free cash flow over the last twelve months, with forecasts projecting a mature profile featuring an initial step-up followed by a decline over the next decade.
Analysts at Simply Wall St present diverging narratives regarding the stock's valuation. A bullish case suggests BMY is 22% undervalued, citing breakthrough partnerships like the BioNTech deal that position the company for leadership in immuno-oncology and radiopharmaceuticals. Conversely, a bearish view argues the stock is 30% overvalued due to impending revenue cliffs associated with the loss of exclusivity for major blockbusters such as Eliquis, Opdivo, and Revlimid after 2026.
Recent clinical progress continues to influence investor sentiment regarding BMY's future cash flows. Positive Phase 3 data for ZENBEXUS in multiple myeloma has strengthened the case for ongoing oncology revenue, while broader efforts in immunology are expected to shift the company's revenue mix and investment needs over time.
📉 Stock trades below DCF intrinsic value despite mature free cash flow of $11.5 billion.
🤝 BioNTech partnership supports bullish view with 22% undervaluation rating in immuno-oncology.
⚠️ Bearish outlook cites 30% overvaluation due to post-2026 revenue cliffs from Eliquis and Opdivo.
🧬 Positive Phase 3 EXCALIBER-RRMM data for ZENBEXUS strengthens oncology cash flow outlook.
📈 Stock gained 51.6% last year driven by new drug data and expanding pipeline.
📉 BMY stock closed at US$63.88, trading below a DCF model's intrinsic value estimate which implies a discount to future cash generation.
💰 The company produced roughly $11.5 billion in free cash flow over the last twelve months with a forecasted mature profile.
🤝 A bullish narrative rates BMY as 22% undervalued, highlighting the BioNTech partnership for industry leadership in immuno-oncology.
⚠️ A bearish narrative rates BMY as 30% overvalued due to severe revenue cliffs expected after 2026 from patent expirations on Eliquis, Opdivo, and Revlimid.
🧬 Recent positive Phase 3 EXCALIBER-RRMM data for ZENBEXUS strengthens the outlook for oncology cash flows.
📈 BMY delivered a 51.6% gain over the past year driven by fresh drug data and an expanding pipeline.
Bullish Signals
Generated $11.5 billion free cash flow last twelve months.
Positive EXCALIBER-RRMM data strengthens oncology revenue case.
Bristol Myers Squibb (BMY) shares closed at USD 63.88 on September 28, 2026, representing a gain of USD 1.02 or 1.62% from the previous session's close of USD 62.86. The stock traded on the New York Stock Exchange as of 20:00:02 UTC.
On September 25, 2026, the company announced positive Phase 3 trial results for its multiple myeloma candidate ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone. The EXCALIBER-RRMM trial evaluated the treatment in 420 patients with relapsed or refractory disease.
The study demonstrated a minimal residual disease-negative complete response rate of 41.10% for the ZENBEXUS combination, compared to 20.70% for the comparator regimen of daratumumab, bortezomib, and dexamethasone. These results were presented at the 2026 International Myeloma Society meeting and published in The Lancet Oncology.
Additionally, Bristol Myers Squibb's board declared a quarterly dividend of USD 0.63 per share on September 16, 2026. This dividend is scheduled to be payable on November 2, 2026, to shareholders of record as of October 2, 2026.
📈 BMY stock closed at $63.88, up 1.62% on September 28, 2026.
💰 BMY declared $0.63 quarterly dividend payable November 2, 2026.
📈 BMY stock closed at USD 63.88 on September 28, 2026, up 1.62% from the prior session.
🔬 Bristol Myers Squibb announced Phase 3 EXCALIBER-RRMM trial results for ZENBEXUS in multiple myeloma.
📊 The ZENBEXUS combination achieved a 41.10% minimal residual disease-negative complete response rate versus 20.70% for the comparator.
📅 Trial data was presented at the 2026 International Myeloma Society meeting and published in The Lancet Oncology.
💰 The company declared a quarterly dividend of USD 0.63 per share payable on November 2, 2026.
Bullish Signals
ZENBEXUS Phase 3 showed 41.10% response rate vs 20.70%.
Stock rose 1.62% to USD 63.88 after trial results.
Bullish Signals
Bristol Myers Squibb reported positive Phase 3 data for ZENBEXUS in multiple myeloma, showing a 41.10% complete response rate versus 20.70% for the comparator.
The company's stock price increased by 1.62% to close at USD 63.88 following the announcement of clinical trial results.
On September 1, 2026, Bristol-Myers Squibb (BMY) paused enrollment in its competing CAR-T program, zola-cel, for autoimmune and neurological conditions. The company cited precautionary measures following observations of 'transient and reversible' inflammatory events, explicitly noting that no patient deaths occurred during this period.
Unlike Novartis, which halted eight trials after three patient deaths from a severe immune reaction, BMY's response is narrower in scope and severity. The firm has not stopped all aspects of its trials but rather limited new enrollment while conducting a safety review to identify effective monitoring or treatment strategies that could allow for a restart.
Market positioning data reveals a divergence in investor sentiment ahead of the public disclosure. Hedge fund interest in BMY declined significantly, with holder counts dropping from 83 to 74 and position value falling from $5.97 billion to $4.79 billion in the second quarter, contrasting with Novartis which saw increased hedge fund accumulation prior to its own setbacks becoming public.
🛑 BMY paused zola-cel enrollment due to transient inflammatory events.
💀 No patient deaths reported for BMY's zola-cel trials.
📉 Hedge fund interest in BMY dropped from $5.97B to $4.79B.
⏳ BMY paused only new enrollment, not all trial activities.
⚖️ BMY faced governance concerns over three-month disclosure delay.
🛑 Bristol-Myers Squibb paused enrollment in its zola-cel autoimmune CAR-T program following observations of transient and reversible inflammatory events.
💀 No patient deaths were reported for BMY's zola-cel trials, distinguishing the safety profile from Novartis' recent fatal immune reactions.
📉 Hedge fund interest in BMY decreased in Q2 2026, with position value dropping from $5.97 billion to $4.79 billion as investors reacted to pipeline uncertainty.
⏳ The company paused only new enrollment rather than halting all trial activities, suggesting a potentially clearer path toward restarting studies if safety protocols are adjusted.
🔬 BMY described the inflammatory events as transient and reversible, indicating a less severe disclosed safety situation compared to Novartis' fatal cases.
⚖️ The pause creates governance concerns regarding disclosure timelines, as BMY waited three months before informing the public despite early June internal notifications.
Bullish Signals
Safety events were transient and reversible.
Trial paused only new enrollment, not all.
Risk Factors
Enrollment paused due to inflammatory events causing delays.
Safety issues delayed public disclosure for three months.
Hedge fund positions dropped from $5.97B to $4.79B.
Bullish Signals
The company reported that observed inflammatory events were transient and reversible, suggesting a manageable safety profile compared to fatal outcomes seen in competitors.
Bristol-Myers Squibb paused only new enrollment rather than stopping all trial activities, preserving ongoing data collection and offering a clearer path toward restarting studies.
Risk Factors
Enrollment was paused in the zola-cel autoimmune CAR-T program following observations of inflammatory events, creating immediate development delays.
The company waited approximately three months to inform the public about safety issues despite internal knowledge in early June, raising governance and reputational concerns.
Hedge fund interest declined significantly in Q2 2026, with position value dropping from $5.97 billion to $4.79 billion, reflecting investor caution regarding pipeline setbacks.
Bristol Myers Squibb (BMY) shares traded on the NYSE on September 25, 2026, closing at USD 61.93, representing a gain of 0.71 percent or USD 0.43 from the prior session's reference price. The stock opened at USD 61.75 and fluctuated between an intraday low of USD 61.39 and a high of USD 62.28 before settling near the upper end of its range. Trading volume for the session stood at approximately 3.97 million shares, indicating moderate liquidity as the stock outperformed the broader S&P 500 ETF (SPY) by 0.24 percentage points.
A significant catalyst driving the positive sentiment was an analyst upgrade from Zacks Research, which changed the rating on BMY from 'hold' to 'strong buy' earlier that day. This upgrade provides a bullish signal regarding the company's future prospects and valuation relative to peers. Additionally, the board declared a quarterly dividend of USD 0.63 with a record date set for October 2, 2026, and an expected payment date of November 2, 2026, offering income support to shareholders.
The broader market context included easing oil prices and Treasury yields, which left defensive healthcare stocks mixed despite major index futures pointing higher. While peers like Pfizer, Merck, and Eli Lilly saw declines or stagnation during the session, BMY managed to post a gain. The company is preparing to report its third-quarter 2026 financial results on October 29, 2026, with a conference call scheduled for 8:00 a.m. ET.
Current pricing places BMY at USD 61.93, which is 9.78 percent below its 52-week high of USD 68.64 but 45.65 percent above its 52-week low of USD 42.52. The stock's performance suggests resilience in a mixed market environment, bolstered by the combination of an analyst upgrade and upcoming dividend distribution. Investors are likely monitoring the upcoming earnings report for further guidance on revenue and margin trends.
📈 Shares rose 0.71% to USD 61.93, outperforming S&P 500.
🚀 Zacks upgraded stock from 'hold' to 'strong buy'.
💰 Declared quarterly dividend of USD 0.63.
📊 Volume hit 3.97M shares; price range USD 61.39-62.28.
🗓️ Q3 2026 earnings scheduled for October 29, 2026.
📈 Bristol Myers Squibb shares rose 0.71 percent to USD 61.93, outperforming the S&P 500 ETF by 0.24 percentage points in New York trading.
🚀 Zacks Research upgraded BMY from 'hold' to 'strong buy', providing a positive analyst sentiment signal for the stock.
💰 The company declared a quarterly dividend of USD 0.63 with an October 2, 2026 record date and November 2 payment date.
📊 Trading volume reached 3,974,531 shares as the stock traded between USD 61.39 and USD 62.28 during the session.
📉 BMY is currently trading 9.78 percent below its 52-week high of USD 68.64 but remains well above its 52-week low.
🗓️ The company is scheduled to report third-quarter 2026 earnings on October 29, 2026, with a conference call at 8:00 a.m. ET.
⚖️ While peers like Pfizer and Merck declined during the session, BMY maintained positive momentum amidst mixed defensive healthcare sentiment.
Bullish Signals
Zacks upgraded shares from 'hold' to 'strong buy'.
Stock gained 0.71% to USD 61.93.
Board declared quarterly dividend of USD 0.63.
Bullish Signals
Zacks Research upgraded Bristol Myers Squibb shares from 'hold' to 'strong buy', signaling improved analyst confidence in the company's prospects.
The stock gained 0.71 percent to USD 61.93, outperforming the broader S&P 500 ETF (SPY) by 0.24 percentage points during the trading session.
The board declared a quarterly dividend of USD 0.63 with a record date of October 2, 2026, providing income support to shareholders.
The article compares Bristol Myers Squibb (BMY) and Pfizer, noting BMY's focus on oncology and immunology versus Pfizer's transformation into high-growth areas like obesity. In fiscal year 2025, BMY reported revenue of nearly $48.2 billion, a slight decline of 0.2%, with net income of approximately $7.1 billion and a net margin of 14.6%. This performance marks a recovery from the previous year's net loss.
Bristol Myers Squibb maintains a debt-to-equity ratio of 2.6x and a current ratio of 1.3x, with free cash flow reaching roughly $12.8 billion. The company faces challenges including pricing pressure from government mandates, patent expirations on blockbuster drugs, and ongoing litigation involving a $6.7 billion legal challenge and a lawsuit from Cytokinetics.
Analysts suggest BMY is a compelling near-term bet due to raised full-year revenue outlooks and impressive growth in newer brands, with Eliquis defying expectations. However, the article notes that BMY was not included in The Motley Fool Stock Advisor's list of top 10 stocks for immediate purchase, contrasting its short-term strength with Pfizer's longer-term transformational potential.
📈 FY 2025 revenue reached $48.2B with a slight 0.2% decline.
💰 Net income hit $7.1B, yielding a 14.6% net margin.
📉 Debt-to-equity ratio stands at 2.6x as of December 2025.
Bristol Myers Squibb (BMY) reported second-quarter 2026 financial results that exceeded market consensus, driving a modest 0.1 percent gain in its share price to close at USD 62.68 on the NYSE. The company posted quarterly earnings per share of USD 2.04, significantly beating the USD 1.60 analyst estimate by USD 0.44, while revenue increased 5.7 percent year over year to reach USD 12.97 billion.
Despite the strong operational performance and a concrete earnings anchor provided by the beat, the stock traded below its 52-week high of USD 68.64, remaining USD 5.96 away from that peak. The market reaction was muted with a volume of 2,184,600 shares, suggesting investors are weighing current profitability against future capital requirements.
Looking ahead to fiscal year 2026, the company provided adjusted EPS guidance ranging between USD 6.75 and USD 7.00, which aligns closely with analyst consensus expectations of USD 6.95. However, management increased its full-year operating expense projection to approximately USD 16.5 billion due to pre-launch activities and development programs, indicating a strategic investment in future growth that impacts near-term margins.
The valuation backdrop shows BMY trading at a price-to-earnings ratio of 13.80 with a market capitalization of USD 128.04 billion. The central tension for investors lies in the company's ability to sustain revenue growth and EPS beats while funding significant operating investments required for upcoming product launches.
📈 BMY Q2 2026 revenue rose 5.7% to USD 12.97 billion.
💰 Non-GAAP EPS hit USD 2.04, beating estimates by USD 0.44.
🔮 FY 2026 adjusted EPS guidance set between USD 6.75 and USD 7.00.
💸 Full-year 2026 operating expenses increased to approximately USD 16.5 billion.
📉 Stock closed at USD 62.68, trading below its 52-week high.
📈 Bristol Myers Squibb reported second-quarter 2026 revenue of USD 12.97 billion, representing a 5.7 percent year-over-year increase.
💰 Non-GAAP earnings per share reached USD 2.04, exceeding the consensus estimate of USD 1.60 by USD 0.44.
📉 The stock closed at USD 62.68 on September 22, 2026, trading below its 52-week high of USD 68.64 despite the earnings beat.
🔮 Fiscal year 2026 adjusted EPS guidance was set between USD 6.75 and USD 7.00, aligning with analyst consensus of USD 6.95.
💸 Operating expenses for full-year 2026 were increased to approximately USD 16.5 billion due to pre-launch activity and development programs.
📊 The company trades at a price-to-earnings ratio of 13.80 with a market capitalization of USD 128.04 billion.
Bullish Signals
Q2 2026 revenue hit $12.97B, up 5.7% YoY.
Non-GAAP EPS of $2.04 beat estimates by $0.44.
FY2026 adjusted EPS guidance covers consensus at $6.95.
Risk Factors
Operating expenses projected to rise to USD 16.5 billion in 2026.
Stock closed at USD 62.68, down from 52-week high of USD 68.64.
Bullish Signals
Bristol Myers Squibb reported second-quarter 2026 revenue of USD 12.97 billion, marking a 5.7 percent year-over-year increase.
Non-GAAP earnings per share reached USD 2.04, significantly beating the consensus estimate of USD 1.60 by USD 0.44.
The company provided fiscal year 2026 adjusted EPS guidance between USD 6.75 and USD 7.00, which encompasses the analyst consensus expectation of USD 6.95.
Risk Factors
Management increased its projection for full-year 2026 operating expenses to about USD 16.5 billion due to pre-launch activity and development programs.
The stock closed at USD 62.68, trading USD 5.96 below its 52-week high of USD 68.64 despite the positive earnings surprise.
Bristol Myers Squibb (BMY) has officially discontinued the development of BMS-986497/ORM-6151, a Phase 1 cancer candidate it licensed from Orum Therapeutics. The asset, described as a degrader-antibody conjugate, was part of a licensing agreement with a headline value referenced at $100 million. The discontinuation was confirmed via a regulatory filing on Thursday, marking the end of human testing for this specific early-stage molecule.
The decision represents a routine portfolio management move rather than a significant corporate setback or existential crisis for the large-cap pharmaceutical company. Bristol Myers Squibb operates with more oncology candidates than it can fund to registration, leading to the pruning of early pipelines. Consequently, the discontinuation does not impact near-term revenue and carries no direct read-through to the company's late-stage programs or overall financial health.
Market reaction to the news was neutral to slightly positive, with BMY shares trading up 0.35% to close at $63.06. Investors appear to have treated the filing as standard housekeeping consistent with the company's scale and development capacity constraints. The move signals a choice regarding where scarce resources are allocated but does not invalidate the broader scientific architecture of degrader-antibody conjugates.
The discontinuation specifically impacts Orum Therapeutics, which retains any cash already paid but loses access to future milestone payments contingent on advancing past Phase 1. For BMY, the primary implication is a reduction in pipeline breadth at an early stage without affecting its core business operations or stock performance.
📉 Bristol Myers Squibb discontinued Phase 1 cancer program BMS-986497/ORM-6151.
💰 Discontinuation prevents future milestone payments from the $100 million licensing deal.
📊 Shares rose 0.35% to $63.06 as investors view cut as routine management.
⚖️ Decision maintains stable stock status with no impact on late-stage oncology.
📉 Bristol Myers Squibb has discontinued development of BMS-986497/ORM-6151, a Phase 1 degrader-antibody conjugate cancer program licensed from Orum Therapeutics.
💰 The asset was part of a licensing deal referenced at $100 million, though the discontinuation prevents the realization of future milestone payments tied to advancement beyond Phase 1.
📊 BMY shares closed higher at $63.06 (up 0.35%), indicating investors viewed the pipeline cut as routine portfolio management rather than a negative financial event.
🔬 The discontinued molecule utilized a novel payload architecture designed to hijack cellular disposal machinery, representing a variation on the crowded antibody-drug conjugate field.
🏢 As a large pharmaceutical company, Bristol Myers Squibb routinely prunes early-stage candidates that do not meet high bar standards for advancing past Phase 1 into registration.
⚖️ The decision does not alter BMY's near-term revenue or signal any issues with its late-stage oncology programs, maintaining the status of the stock as stable.
Bullish Signals
Shares rose 0.35% to $63.06, showing investor confidence in pipeline cut.
Early-stage asset drop won't affect near-term revenue or late-stage programs.
Risk Factors
BMS-986497/ORM-6151 development terminated in Phase 1.
Future milestone payments for this asset lost.
Bullish Signals
Bristol Myers Squibb shares closed up 0.35% at $63.06, reflecting investor confidence that the pipeline cut is a routine portfolio management decision rather than a setback.
The discontinuation of an early-stage Phase 1 asset has no impact on the company's near-term revenue or its late-stage program portfolio.
Risk Factors
Bristol Myers Squibb has terminated development of BMS-986497/ORM-6151, a licensed degrader-antibody conjugate candidate in Phase 1 human testing.
The discontinuation means the company will not realize future milestone payments contingent on advancing this specific asset beyond Phase 1.
Bristol-Myers Squibb (BMY) shares closed at USD 62.84 on September 17, 2026, trading approximately 8.4% below their 52-week high but well above the low. The company reported strong second-quarter 2026 financial performance with revenue rising 5.7% year-over-year and achieving a profit margin of 25.57%. These solid operational metrics provided a quantitative counterweight to recent negative developments in its drug development pipeline, helping to stabilize investor sentiment despite the halt on specific assets.
The primary headwind for BMY involves the discontinuation of ORM-6151, a blood cancer candidate licensed from Orum Therapeutics. After reviewing early Phase 1 clinical data, Bristol-Myers Squibb decided to return development rights to the biotech partner, ending a program where it had previously committed USD 100 million. While this setback negatively impacted Orum Therapeutics' stock price by over 33%, analysts view the impact on BMY as contained due to the depth of its broader oncology and immunology portfolios.
From a valuation perspective, BMY trades at a significant discount to the broader large-cap pharmaceutical industry, with a forward price-to-earnings ratio of 9.58 times compared to an industry average of 18.01 times. The stock has gained 16.5% year-to-date, outpacing the broader industry's 5.7% growth, suggesting investors have already rewarded the company for its operational delivery. Analyst consensus remains constructive with rising earnings estimates for 2026 and 2027, though the Zacks Rank is currently a 'Hold' pending further pipeline progress.
Looking ahead, the next scheduled earnings release is set for October 29, 2026. With a market capitalization of approximately USD 129.46 billion, BMY remains a core constituent of the S&P 500 Health Care sector. Investors are weighing the near-term pipeline volatility against the company's attractive valuation and strong mid-single-digit revenue growth, positioning the stock in the upper half of its 52-week trading range.
📉 BMY shares closed at USD 62.84, trading 8.4% below the 52-week high.
💰 Q2 2026 revenue rose 5.7% with a robust 25.57% profit margin.
🚫 BMY discontinued ORM-6151 development and returned rights to Orum Therapeutics.
📊 Stock trades at forward P/E of 9.58x, well below industry average.
🚀 Shares gained 16.5% year-to-date, outperforming the broader pharmaceutical sector.
📉 BMY shares closed at USD 62.84 on September 17, 2026, trading 8.4% below the 52-week high but significantly above the low.
💰 Q2 2026 revenue increased by 5.7% with a robust profit margin of 25.57%, demonstrating strong operational efficiency.
🚫 The company discontinued development of ORM-6151 and returned rights to Orum Therapeutics after reviewing Phase 1 data.
💸 BMY had previously committed USD 100 million to the ORM-6151 degrader-antibody conjugate program before pulling back.
📊 The stock trades at a forward P/E of 9.58x, which is substantially lower than the industry average of 18.01x.
🚀 Shares have gained 16.5% year-to-date, outperforming the broader pharmaceutical industry's 5.7% growth rate.
📈 Analyst consensus estimates for 2026 earnings per share rose to USD 6.91 from USD 6.34 over the past 60 days.
🗓️ The next earnings report is scheduled for release on October 29, 2026.
🏢 BMY maintains a market capitalization of approximately USD 129.46 billion as of September 18, 2026.
⚖️ The stock currently holds a Zacks Rank of 3 (Hold), reflecting a balanced analyst stance on valuation and pipeline.
Bullish Signals
Revenue grew 5.7% with 25.57% profit margin in Q2 2026.
Risk Factors
Discontinued ORM-6151 development after Phase 1 data review.
Ended $100M program commitment following pipeline asset pivot.
Bullish Signals
Bristol-Myers Squibb delivered strong Q2 2026 financial results with revenue growth of 5.7% and a profit margin of 25.57%, supporting the stock price.
The company trades at a significant valuation discount to the industry average, with a forward P/E ratio of 9.58x compared to an industry average of 18.01x.
Shares have appreciated 16.5% year-to-date, significantly outperforming the broader pharmaceutical sector's 5.7% growth.
Analyst consensus estimates for 2026 earnings per share have increased to USD 6.91, indicating constructive expectations for future performance.
The stock is trading in the upper half of its 52-week range, suggesting investor confidence despite specific pipeline setbacks.
Risk Factors
Bristol-Myers Squibb discontinued development of ORM-6151 and returned rights to Orum Therapeutics after reviewing early Phase 1 clinical data.
The company ended a program where it had previously committed USD 100 million, reflecting a strategic pivot following the review of pipeline assets.
Bristol-Myers Squibb (BMY) shares closed at USD 62.84 on September 17, 2026, reflecting a mixed market reaction where strong second-quarter financial performance was partially offset by the decision to halt development of the oncology candidate ORM-6151. The company reported Q2 2026 revenue of USD 12.97 billion, representing a 5.7% year-over-year increase that significantly beat analyst expectations by 12.9%. Earnings per share reached USD 2.04, surpassing the consensus estimate of USD 1.60 and yielding a profit margin of 25.57%.
The strategic decision to discontinue ORM-6151, a blood cancer degrader-antibody conjugate licensed from Orum Therapeutics, removes a potential future revenue stream for Bristol-Myers Squibb. This development also eliminates up to USD 80 million in contingent milestone payments owed to the partner, though the upfront payment of USD 100 million previously received remains intact. The halt follows a review of Phase 1 clinical data conducted across the United States, Europe, and Canada.
Despite the pipeline setback, the company's core portfolio continues to generate substantial cash flow, supported by a fresh dividend declaration of USD 0.63 per share with an ex-dividend date of October 2, 2026. Investors view the stock as modestly undervalued compared to peers like AbbVie, trading at a forward price-earnings multiple of 9.2 times versus 18.5 times for the competitor. The market capitalization stands at approximately USD 129.46 billion.
Looking ahead, Bristol-Myers Squibb is scheduled to release Q3 2026 results on October 29, 2026, which will provide clarity on whether the strong revenue trajectory can be sustained amidst pipeline adjustments. Additionally, a Phase 3 study for the investigational agent izalontamab brengitecan in combination with osimertinib is set to commence on September 30, 2026, highlighting the diversified nature of the research portfolio as the company manages risks associated with specific asset discontinuations.
📉 BMY stock closed at $62.84, trading 8.4% below its 52-week high.
💰 Q2 2026 revenue hit $12.97 billion, beating estimates by 12.9%.
📊 EPS reached $2.04, exceeding consensus with a 25.57% profit margin.
⚠️ BMY halted ORM-6151 development, saving up to $80 million in milestones.
📈 Board declared a $0.63 cash dividend with an ex-date of Oct 2.
📉 Bristol-Myers Squibb stock closed at USD 62.84 on September 17, 2026, trading roughly 8.4% below its 52-week high of USD 68.64.
💰 The company reported Q2 2026 revenue of USD 12.97 billion, up 5.7% year over year and beating analyst expectations by 12.9%.
📊 Earnings per share reached USD 2.04, exceeding the consensus estimate of USD 1.60 with a profit margin of 25.57%.
⚠️ Bristol-Myers Squibb decided to halt development of ORM-6151, a blood cancer candidate licensed from Orum Therapeutics, after reviewing Phase 1 data.
💸 The discontinuation of ORM-6151 eliminates up to USD 80 million in contingent milestone payments for the partner company.
📈 The board declared a cash dividend of USD 0.63 per share with an ex-dividend date of October 2, 2026.
🔬 A Phase 3 study for izalontamab brengitecan in combination with osimertinib is scheduled to start on September 30, 2026.
📉 Bristol-Myers Squibb trades at a forward price-earnings multiple of 9.2 times, significantly lower than peer AbbVie's 18.5 times.
📅 The company plans to release Q3 2026 financial results on October 29, 2026.
🏥 Market capitalization is approximately USD 129.46 billion as of September 18, 2026.
Bullish Signals
Q2 2026 revenue hit USD 12.97B, beating estimates by 12.9%.
EPS reached USD 2.04, surpassing consensus by USD 0.44.
Profit margin expanded to a robust 25.57% in Q2 2026.
Board declared fresh cash dividend of USD 0.63 per share.
Analysts peg fair value at USD 66.21, suggesting undervaluation.
Bristol-Myers Squibb (BMY) shares gained momentum following the release of positive two-year clinical trial data for its immunology drug Sotyktu in psoriatic arthritis. The Phase 3 POETYK PsA-2 study and its open-label extension demonstrated durable efficacy and a consistent safety profile, with results presented at the Congress of Clinical Rheumatology - West. This development serves as a new catalyst for the company's efforts to expand Sotyktu beyond its existing indications in plaque psoriasis.
Fundamentally, Bristol-Myers Squibb reported robust second-quarter 2026 financial results that exceeded market expectations. Revenue rose 6 percent year-over-year to USD 12.97 billion, while non-GAAP earnings per share (EPS) increased to USD 2.04, beating the consensus estimate of USD 1.60 by a significant margin. The Growth Portfolio drove this expansion with a 15 percent revenue increase, whereas the Legacy Portfolio declined 4 percent due to generic erosion in oncology assets like Revlimid and Pomalyst.
The company maintains a sustainable capital return profile with a quarterly dividend of USD 0.63 per share, offering a yield of approximately 3.95 percent. Analyst consensus rates BMY as a Moderate Buy with an average target price near USD 66.71, implying upside potential from the recent trading levels around USD 63.60. However, investors must monitor ongoing generic competition pressures and valuation metrics that suggest the stock trades slightly above its intrinsic value estimate.
📈 Q2 2026 revenue rose 6% to USD 12.97 billion driven by Growth Portfolio.
💊 Sotyktu shows durable efficacy and favorable safety in POETYK PsA-2 study.
📉 Legacy Portfolio fell 4% due to generic erosion of Revlimid and Pomalyst.
💰 Quarterly dividend maintained at USD 0.63 with ~3.95% yield for shareholders.
Bristol-Myers Squibb reported Q2 2026 revenue of USD 12.97 billion, a 6 percent year-over-year increase driven by strong growth in its Growth Portfolio.
Non-GAAP EPS for the quarter reached USD 2.04, significantly beating the consensus estimate of USD 1.60 and demonstrating robust profitability.
Positive two-year clinical trial data for Sotyktu in psoriatic arthritis demonstrated durable efficacy and a consistent safety profile, serving as a new catalyst.
Eliquis revenue within the Legacy Portfolio grew 22 percent to USD 4.48 billion, highlighting the strength of the cardiovascular franchise.
The company maintained its quarterly dividend at USD 0.63 per share with a sustainable payout ratio of 39 percent and a three-year growth rate of 4.4 percent.
Risk Factors
The Legacy Portfolio declined 4 percent to USD 5.42 billion due to ongoing generic erosion affecting oncology assets Revlimid and Pomalyst.
Valuation analysis suggests the stock trades approximately 12.4 percent above its GF Value estimate, which could limit near-term upside if earnings growth slows.
Bristol Myers Squibb (BMY) announced that its Board of Directors has declared a quarterly dividend of $0.63 per share on its common stock. This declaration reinforces the company's ongoing strategy to return value to shareholders through consistent cash distributions.
The dividend is scheduled to be payable on November 2, 2026, to stockholders of record as of the close of business on October 2, 2026. This payment maintains the established cadence of quarterly distributions previously set by the company.
Alongside the financial announcement, Bristol Myers Squibb reiterated its core mission to discover, develop, and deliver innovative medicines for serious diseases. The company emphasized that this commitment is supported by continued investment in research and bold scientific advancements across its global portfolio.
📈 BMY declared $0.63 quarterly dividend payable Nov 2, 2026.
📅 Record date is October 2, 2026 for eligible shareholders.
💰 Move reinforces strategy of returning value via cash distributions.
🔬 Company reaffirms mission to deliver innovative medicines globally.
📈 BMY declared a quarterly dividend of $0.63 per share on common stock.
📅 The dividend will be payable on November 2, 2026, to shareholders of record as of October 2, 2026.
💰 This move reinforces Bristol Myers Squibb's ongoing strategy of returning value to shareholders through regular cash distributions.
🔬 The company reaffirmed its mission to deliver innovative medicines for serious diseases supported by global R&D investments.
Bullish Signals
Declared $0.63 quarterly dividend.
Maintained distribution cadence.
Bullish Signals
Bristol Myers Squibb declared a quarterly dividend of $0.63 per share, reinforcing its commitment to returning value to shareholders through consistent cash distributions.
The company maintained its established cadence of quarterly distributions, signaling financial stability and confidence in future cash flows.
Bristol Myers Squibb announced positive registrational results from its Phase 2 QUINTESSENTIAL study evaluating arlocabtagene autoleucel in heavily pretreated multiple myeloma patients. The trial met both its primary and secondary endpoints, demonstrating the efficacy of this CAR T therapy for a difficult-to-treat patient population.
The company reported that the safety profile of the treatment aligns with expectations based on prior data. These results are set to be presented at an upcoming medical conference, providing further validation for the drug's potential in the oncology market.
✅ Trial met primary and secondary endpoints in heavily pretreated multiple myeloma patients.
🛡️ CAR T therapy safety profile aligns with company expectations.
📅 Results will be presented at an upcoming medical conference.
📈 Bristol Myers Squibb announced positive registrational outcomes from its Phase 2 QUINTESSENTIAL study for arlocabtagene autoleucel.
✅ The trial met both primary and secondary endpoints in heavily pretreated multiple myeloma patients.
🛡️ The safety profile of the CAR T therapy aligns with company expectations.
📅 Results will be presented at an upcoming medical conference.
Bullish Signals
BMS Phase 2 QUINTESSENTIAL study met endpoints.
Drug showed efficacy in heavily pretreated myeloma.
Bullish Signals
Bristol Myers Squibb achieved positive results in its registrational Phase 2 QUINTESSENTIAL study for arlocabtagene autoleucel, meeting primary and secondary endpoints.
The drug demonstrated efficacy in heavily pretreated multiple myeloma patients, a challenging therapeutic area.
Bristol Myers Squibb (NYSE: BMY) reported encouraging mid-stage trial results for its experimental CAR-T cell therapy, arlo-cel, in patients with advanced multiple myeloma who have exhausted four prior treatment classes. The therapy met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in overall response rates, while also achieving a key secondary goal of complete elimination of detectable cancer in some patients.
The results strengthen BMY's position in the competitive oncology market, particularly within the difficult-to-treat multiple myeloma segment where unmet medical need remains high. Arlo-cel targets GPRC5D on cancer cells using a patient's own immune system, offering a potential new growth driver to diversify revenue beyond existing blockbuster medicines. The company plans to present full data at an upcoming medical conference, though detailed response rates and survival metrics have not yet been released.
Despite the positive mid-stage signals, analysts note that commercial success depends on translating these results into regulatory approval and sustained sales in a crowded landscape. Competition from other CAR-T therapies and newer immune-based treatments poses challenges, as does the practical complexity of CAR-T administration compared to oral or injectable alternatives. BMY must demonstrate clear advantages in effectiveness, durability, and safety to secure a meaningful market share.
While this development is viewed as a meaningful win for BMY's pipeline and long-term growth story, it is not yet considered a major commercial breakthrough. Investors are advised to await the detailed clinical data presentation to assess the durability of responses before judging the full potential of the asset. The article concludes that while risks remain regarding later-stage trials and competition, arlo-cel adds confidence to BMY's CAR-T program.
📈 Arlo-cel met primary goals in advanced multiple myeloma trial after four prior treatments.
🔬 Therapy showed significant response rates with some patients achieving complete cancer elimination.
⚠️ Commercial success depends on proving advantages over competing CAR-T therapies and new treatments.
📊 Program aims to diversify oncology revenue beyond current blockbuster medicines for BMY.
⚠️ Mid-stage results do not guarantee later-stage trial success or regulatory approval for arlo-cel.
📈 Bristol Myers Squibb's experimental CAR-T therapy arlo-cel met its primary goal in a mid-stage trial for advanced multiple myeloma patients who had failed four prior treatments.
🔬 The therapy achieved a statistically significant and clinically meaningful improvement in overall response rates, with some patients achieving complete elimination of detectable cancer.
📅 BMY plans to present full trial results at an upcoming medical conference, though detailed numbers on progression-free survival and safety have not yet been released.
💊 Arlo-cel targets GPRC5D on cancer cells by modifying a patient's own immune cells, addressing a significant unmet medical need in a difficult-to-treat population.
📉 The multiple myeloma market faces intense competition from existing CAR-T therapies and newer immune-based treatments, including recent strong results from AbbVie's etentamig.
⚠️ Commercial success for arlo-cel depends on demonstrating clear advantages in effectiveness, durability, safety, and treatment convenience against competing options.
📊 The program represents a potential new growth driver to diversify BMY's oncology revenue as the company seeks expansion beyond its current blockbuster medicines.
🛑 While mid-stage results lower development risk, they do not guarantee success in later-stage trials or regulatory approval for this cell therapy candidate.
Bullish Signals
Arlo-cel CAR-T therapy met primary endpoint in multiple myeloma trial.
Therapy achieved complete cancer elimination in some patients.
Results strengthen oncology market position and diversify revenue.
Risk Factors
Clinical data pending creates investor uncertainty on durability.
Complex CAR-T admin requires proving advantage over rivals.
Bullish Signals
Bristol Myers Squibb's experimental CAR-T therapy arlo-cel met its primary endpoint in a mid-stage trial, showing statistically significant and clinically meaningful improvement in overall response rates for advanced multiple myeloma patients.
The therapy achieved a key secondary goal of complete elimination of detectable cancer in some patients, suggesting the potential for deep responses in a difficult-to-treat population.
Encouraging trial results strengthen BMY's position in the competitive oncology market and provide another potential long-term growth asset to diversify revenue beyond existing blockbuster medicines.
Risk Factors
Detailed clinical data, including specific response rates, progression-free survival, overall survival, and detailed safety profiles, have not yet been released, leaving investors uncertain about the durability of the therapy's benefits.
Practical issues associated with CAR-T therapies, such as complex administration processes compared to non-CAR-T alternatives, require BMY to demonstrate sufficient advantages in effectiveness and treatment experience to stand out.
Bristol Myers Squibb (BMY) reported strong quarterly financial results, beating analyst expectations with earnings per share of $2.04 against a consensus of $1.60 and revenue rising 5.7% year-over-year to $12.97 billion. The company maintains a robust balance sheet with a quick ratio of 1.38 and a market capitalization of approximately $136.56 billion, while offering shareholders a quarterly dividend of $0.63 for an annualized yield of 3.8%.
Institutional investor activity shows mixed signals regarding the stock's near-term trajectory. Mid American Wealth Advisory Group reduced its position by 27.8%, selling over 22,000 shares, while several other funds including Swiss RE and Darwin Wealth Management initiated new positions valued between $25,000 and $32,000 during the quarter. Analyst consensus remains a 'Moderate Buy' with a price target of $66.06, though individual targets vary from $59 to $73.
The company faces specific headwinds including safety concerns that led to a pause in zola-cel autoimmune cell-therapy trials and looming patent expiries for legacy drugs like Eliquis and Opdivo. Conversely, the stock is supported by strong margins, low valuation metrics relative to peers, and positive analyst sentiment following recent upgrades from Sanford Bernstein and JPMorgan Chase.
Bristol Myers Squibb is expanding its pipeline into new therapeutic areas, such as a Phase 2 trial for depression therapy, aiming to offset declines in older medicines. While insider selling occurred with SVP Phil Holzer reducing his holdings, the broader institutional ownership stands at 76.41%, indicating continued significant interest from major investors despite sector-wide pressure.
📈 BMY EPS beat estimates at $2.04 with revenue up 5.7%.
💰 Quarterly dividend of $0.63 offers a 3.8% annualized yield.
🔬 Enrollment paused in zola-cel trials due to inflammatory safety concerns.
⚠️ Risks include legacy drug declines for Opdivo and Eliquis patents.
📈 Analysts upgraded BMY with a consensus price target of $66.06.
📈 BMY reported quarterly EPS of $2.04, significantly beating the $1.60 consensus estimate, while revenue grew 5.7% year-over-year to $12.97 billion.
💰 The company pays a quarterly dividend of $0.63, representing a 3.8% annualized yield with a payout ratio of 55.51%.
📉 Mid American Wealth Advisory Group cut its BMY position by 27.8%, selling 22,416 shares and retaining approximately $3.35 million worth of stock.
🔬 Bristol Myers Squibb paused enrollment in zola-cel autoimmune cell-therapy trials following the identification of inflammatory safety concerns.
⚠️ Investors face risks from legacy-drug declines, specifically Opdivo, and future patent expiry for Eliquis.
📊 The stock carries a 'Moderate Buy' consensus rating with a price target of $66.06, though analyst targets range widely from $59 to $73.
🚀 BMY is expanding its pipeline into the depression market via a new Phase 2 trial evaluating a therapy in that large potential market.
📈 Analyst sentiment improved recently with upgrades from Sanford Bernstein and JPMorgan Chase raising price targets and ratings.
💼 Institutional ownership remains high at 76.41%, with several funds like Swiss RE initiating new positions valued around $25,000.
📉 Insider selling occurred as SVP Phil Holzer sold 500 shares, reducing his ownership by 2.88% in a transaction worth $33,750.
Bullish Signals
EPS beat at $2.04 vs $1.60 consensus with 5.7% revenue growth.
Defensive profile offers 3.8% dividend yield on low valuation.
Strong liquidity shown by quick ratio of 1.38 and 18.87% net margin.
Upgrades from Sanford Bernstein and JPMorgan raise price target to $73.
New depression therapy trial expands growth into large potential market.
Risk Factors
Zola-cel trials paused due to serious inflammatory side effects.
Revenue risks from Opdivo declines and Eliquis patent expiry.
Mid American Wealth reduced stake by 27.8% selling 22k shares.
Healthcare sector downturn adds pressure to stock performance.
SVP Phil Holzer sold 500 shares in late August.
Bullish Signals
Bristol Myers Squibb beat earnings expectations with EPS of $2.04 versus the $1.60 consensus and revenue growth of 5.7% to $12.97 billion.
The company offers a defensive income profile with a quarterly dividend of $0.63 yielding 3.8% annually and a low valuation relative to peers.
Strong financial health is evidenced by a quick ratio of 1.38, current ratio of 1.53, and a net margin of 18.87%.
Analyst sentiment turned more bullish recently with Sanford Bernstein upgrading to 'outperform' and JPMorgan raising its price target to $73.
The company is diversifying growth by launching a Phase 2 trial for depression therapy, expanding into a large potential market.
Institutional confidence is supported by new positions from funds like Swiss RE and Darwin Wealth Management totaling over $50,000 in the quarter.
Risk Factors
Bristol Myers Squibb paused its zola-cel autoimmune cell-therapy trials after safety surveillance identified serious inflammatory side effects.
The company faces significant revenue risks from legacy-drug declines, including Opdivo, and the future patent expiry of Eliquis.
Mid American Wealth Advisory Group significantly reduced its stake by 27.8%, selling over 22,000 shares in the second quarter.
The wider healthcare sector traded lower recently, adding industry-level pressure to BMY's stock performance.
Insider selling activity was noted as SVP Phil Holzer sold 500 shares of the company's stock in late August.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)